Myocardial infarction (heart attack) occurs when coronary blood flow is severely reduced or blocked, causing ischemic injury and necrosis of heart muscle. It is a major cause of cardiovascular morbidity and mortality.
mRNA medicine and spatiotemporal drug delivery systems are expanding options for cardiovascular disease. The sources describe preclinical proof-of-concept, clinical trials and programmable cardiac repair platforms.
A study in the American Journal of Medicine found that U.S. adults with the highest ultraprocessed food intake had higher cardiovascular disease risk. Mean ultraprocessed food intake was 26.1% of total energy.
Phase 3 OCEANIC-STROKE data showed asundexian plus antiplatelet therapy reduced recurrent ischemic stroke versus placebo. Major bleeding rates were similar between groups.
A study of over 83,000 women found that initiating hormone therapy after age 65 significantly increases risks for cancer and cerebrovascular events, reinforcing current guidelines that discourage starting systemic hormone therapy after age 60.
CellProthera plans to launch a Phase III trial of its ProtheraCytes stem cell therapy for heart failure patients in Q1 2027, enrolling 300-400 patients across 50 sites. The company acquired a transendocardial catheter from Celyad Oncology for €5 million to enable precise delivery of the therapy.
The global 3D bioprinted human tissue market is projected to grow from $2.5 billion in 2025 to $3.9 billion by 2035 at a 4.6% CAGR, driven by regenerative medicine demand and advances in hybrid hydrogel materials for tissue engineering.
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
A study published in JAMA Cardiology found that semaglutide would be cost-effective for secondary cardiovascular disease prevention in U.S. adults with overweight or obesity at an 18% price reduction or at the current cash price of $5,988 annually.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07563231 |
ABLUMINUS NP Polymer Free Sirolimus-Eluting Stent Registry at Geneva University Hospitals (ABLUMINUS-GVA) |
NOT_YET_RECRUITING | |
| NCT07549282 |
Use Dexmedetomidine To Protect Myocardial Injury Evaluation |
NOT_YET_RECRUITING | PHASE4 |
| NCT07541014 |
TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome |
RECRUITING | NA |
| NCT07527494 |
Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction |
NOT_YET_RECRUITING | NA |
| NCT07519590 |
One-Time Complete Revascularization Versus Staged PCI in MVD During Pharmaco-Invasive STEMI Strategy |
COMPLETED | NA |
| NCT07465692 |
Long-term Results of Rehabilitation of Patients With Myocardial Infarction After Coronary Artery Stenting. The Register. |
ACTIVE_NOT_RECRUITING | NA |
| NCT07457320 |
Development and Validation of a Multimodal Artificial Intelligence Model for Early Prediction of Acute Myocardial Infarction |
NOT_YET_RECRUITING | |
| NCT07405788 |
Percutaneous Coronary Intervention for Myocardial Infarction at Fujian Provincial Hospital |
ACTIVE_NOT_RECRUITING | NA |
| NCT07402642 |
Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome |
RECRUITING | NA |
| NCT07395648 |
Foundation Model for Post-MI Cardiovascular Event Alert Using Huawei Watch |
NOT_YET_RECRUITING | NA |
